BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 24370861)

  • 1. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
    Jodele S; Fukuda T; Vinks A; Mizuno K; Laskin BL; Goebel J; Dixon BP; Teusink A; Pluthero FG; Lu L; Licht C; Davies SM
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):518-25. PubMed ID: 24370861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
    Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
    Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.
    Jodele S; Dandoy CE; Lane A; Laskin BL; Teusink-Cross A; Myers KC; Wallace G; Nelson A; Bleesing J; Chima RS; Hirsch R; Ryan TD; Benoit S; Mizuno K; Warren M; Davies SM
    Blood; 2020 Mar; 135(13):1049-1057. PubMed ID: 31932840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.
    Schoettler M; Lehmann L; Li A; Ma C; Duncan C
    Biol Blood Marrow Transplant; 2019 May; 25(5):e163-e168. PubMed ID: 30639820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eculizumab and thrombotic microangiopathy after hematopoietic stem cell transplantation: A report on its efficacy and safety in two pediatric patients.
    Genere L; Bacchetta J; Bertrand Y; Javouhey E; Cheikh N; Sellier-Leclerc AL
    Arch Pediatr; 2018 Nov; 25(8):485-488. PubMed ID: 30340942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Eculizumab in Pediatric Patients with High-Risk Transplantation-Associated Thrombotic Microangiopathy: Outcomes and Risk Factors Associated with Response and Survival. A Retrospective Study on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
    Benítez Carabante MI; Bueno D; Alonso García L; López Torija I; Marsal J; Fernandez Navarro JM; Uria Oficialdegui ML; Panesso M; Molina B; Beléndez Bieler C; Palomo P; Pérez Martínez A; Diaz-de-Heredia C
    Transplant Cell Ther; 2024 Jun; 30(6):601.e1-601.e13. PubMed ID: 38521410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eculizumab therapy.
    Cataland SR
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):438-9. PubMed ID: 24534107
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC.
    de Fontbrune FS; Galambrun C; Sirvent A; Huynh A; Faguer S; Nguyen S; Bay JO; Neven B; Moussi J; Simon L; Xhaard A; Resche-Riggon M; O'Meara A; Fremeaux-Bacchi V; Veyradier A; Socié G; Coppo P; de Latour RP
    Transplantation; 2015 Sep; 99(9):1953-9. PubMed ID: 25651309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis.
    Zhang R; Zhou M; Qi J; Miao W; Zhang Z; Wu D; Han Y
    Front Immunol; 2020; 11():564647. PubMed ID: 33552043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eculizumab treatment in paediatric patients diagnosed with aHUS after haematopoietic stem cell transplantation: a HSCT-TMA case series from Japanese aHUS post-marketing surveillance.
    Ito S; Saito A; Sakurai A; Watanabe K; Karakawa S; Miyamura T; Yokosuka T; Ueki H; Goto H; Yagasaki H; Kinoshita M; Ozeki M; Yokoyama N; Teranishi H
    Bone Marrow Transplant; 2024 Mar; 59(3):315-324. PubMed ID: 38102212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT.
    Mizuno K; Dandoy CE; Teusink-Cross A; Davies SM; Vinks AA; Jodele S
    Blood Adv; 2022 Mar; 6(5):1454-1463. PubMed ID: 35008105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approaching treatment of transplant-associated thrombotic Microangiopathy from two directions with Eculizumab and transitioning from Tacrolimus to Sirolimus.
    Jan AS; Hosing C; Aung F; Yeh J
    Transfusion; 2019 Nov; 59(11):3519-3524. PubMed ID: 31587288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Eculizumab in Thrombotic Microangiopathy Associated with Hematopoietic Stem Cell Transplantation.
    Demircioglu S; Dogan A; Demir C
    J Coll Physicians Surg Pak; 2021 Nov; 31(11):1359-1361. PubMed ID: 34689499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic stem cell transplantation-associated thrombotic microangiopathy accompanied by renal arteriolar C4d deposition.
    Sakamoto K; Imamura T; Osone S; Nishimura A; Nishida M; Ishida H; Hosoi H
    Pediatr Transplant; 2015 Jun; 19(4):E97-100. PubMed ID: 25735190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compassionate Use Narsoplimab for Severe Refractory Transplantation-Associated Thrombotic Microangiopathy in Children.
    Schoettler ML; Patel S; Bryson E; Deeb L; Watkins B; Qayed M; Chandrakasan S; Fitch T; Silvis K; Jones J; Chonat S; Williams KM
    Transplant Cell Ther; 2024 Mar; 30(3):336.e1-336.e8. PubMed ID: 38145741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transplant-Associated Thrombotic Microangiopathy in the Context of Allogenic Hematopoietic Stem Cell Transplantation: Where We Stand.
    Lazana I
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.
    Kello N; Khoury LE; Marder G; Furie R; Zapantis E; Horowitz DL
    Semin Arthritis Rheum; 2019 Aug; 49(1):74-83. PubMed ID: 30598332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired Complement Regulatory Gene Mutations and Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy.
    Ardissino G; Salardi S; Berra S; Colussi G; Cugno M; Zecca M; Giglio F; Peccatori J; Diral E; Tel F; Clivio A; Tedeschi S
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1580-1582. PubMed ID: 28522344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eculizumab treatment of thrombotic microangiopathy in a patient with ulcerative colitis.
    Øzbay LA
    Clin J Gastroenterol; 2020 Jun; 13(3):344-348. PubMed ID: 31612381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.